The biotech space ended on a very BULLIsh note last week and this underfollowed biotech company may be the next to see blue-sky growth
Greetings All,
As 2023 inches closer to an end, there are still a few weeks to go to uncover phenomenal and promising companies to keep your eyes on this year and beyond.
The biotech arena had an exciting finish in the last week after Big Pharma’s $10.1 billion deal splash.
Stocks in the space saw a lift on the news that AbbVie announced plans to buy cancer developer ImmunoGen for $31.26 a share. This marks about a 95% premium to Immunogen’s closing price last Wednesday!
Download Research Report
With momentum going, now is the time to have underfollowed biotech company Phio Pharmaceuticals Corp. on your radar.
The NASDAQ-traded stock trades under the ticker symbol “PHIO.”
PHIO is a clinical-stage biotech co-founded by the Nobel scientist who discovered RNA interference.
The stock is currently trading a little over $1 and carries a “STRONG BUY” rating at NASDAQ.com.
In an August report, Vernon Bernardino from H.C. Wainwright reiterated a “BUY” rating on Phio Pharmaceuticals (PHIO – Research Report), with a price target of $6.00. According to TipRanks, Bernardino is a 4-star analyst with an average return of 10.0%.
A $6 price target indicates a potential upside of 400%! And this is just one reason to have PHIO on your radar!
Who is Phio Pharmaceuticals Corp.?
PHIO is a clinical-stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells.
What is Intasyl?
INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics.
INTASYL drugs are designed to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
INTASYL is a patented precision delivery technology that delivers uniquely designed gene-silencing compounds to any gene target in the human genome.
It effectively targets messenger RNA to suppress specific proteins, genetically encoded in the DNA, that can interfere with the body’s immune cells in killing cancer cells, resulting in the reduction of specific protein targets. It has been safely tested in human trials in >170 patients.
The INTASYL technology facilitates the creation of unique, chemically modified siRNA compounds (INTASYL compounds), which can be delivered to a broad range of cell types and tissues without the need for enhancements. INTASYL’s innovative approach features a simplified chemical composition, effectively reducing toxicity and enhancing tolerability and efficacy. This technology is adaptable to both intra-tumoral and adoptive cell therapy (ACT) applications, ensuring a versatile and potent therapeutic platform for gene silencing.
See how it works in this video HERE:
Key Clinical Initiatives & Programs:
PH-762
The Phase 1b trial is a non-comparative study of neoadjuvant monotherapy using PH-762 in adult patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. The trial is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose or dose range for continued study of PH-762.
PH-894
PH-894 is designed to silence the BRD4 protein. Overexpression of BRD4 is often associated with cancer progression, invasion, and metastasis. What sets PH-894’s approach to silencing BRD4 apart is its dual activity in suppressing BRD4 in both T cells and in tumor cells: PH-894’s suppression of BRD4 in T cells results in T cell activation; additionally, suppression of BRD4 in tumor cells results in tumors becoming more sensitive to T-cell killing.
A Big Development on PH-762:
PH-762, the company’s lead pipeline product, has received an investigational new drug (IND) application clearance from the FDA to initiate a clinical study on skin cancer indications.
The FDA's clearance of the IND application for PH-762 marks a significant step toward the company's evolution from drug discovery to clinical development.
And recently… the company enrolled the first patient in the company’s U.S. clinical trial with PH-762!
“The initiation of enrollment in this trial represents a milestone as we develop PH-762 for the treatment of squamous cell and other skin cancers. We are optimistic that this novel, alternative immuno-oncology therapy may offer patients and their care providers, enhanced therapeutic outcomes while minimizing invasive intervention,” said President & CEO, Robert Bitterman.
Favorable Data on Cancer Drug Candidate PH-894:
Data from the first study showed that melanoma cells treated with PH-894 enhance their recognition of immune cells. This, in turn, increases their susceptibility to destruction by T cells.
Based on this data, management concluded that PH-894 offers a strategy to reduce BRD4 expression (a protein associated with cancer growth) and simultaneously boost the immune response to cancer cells while minimizing the toxicities commonly associated with traditional systemic therapies.
Data from another study demonstrated the effectiveness of PH-894 as an antitumor cytotoxic agent, i.e., directly killing tumor cells!
This is based on in vitro tests conducted by management on multiple cancer cell lines (like breast cancer, lung cancer and ovarian cancer, among others) wherein treatment with PH-894 induces concentration-associated apoptosis (i.e., the process of programmed cell death).
In Summary…
t’s hard to match the importance of the cancer realm in the biotech arena. Cancer is a disease that has even the biggest biotech companies scrambling to find treatments for.
With two exciting candidates in its pipeline and studies underway, PHIO is a biotech company to keep your eyes closely on! Any encouraging data could be a catalyst for building shareholder value.
Keep in mind that PHIO has a $6 price target! This is one biotech company to not dismiss as 2023 comes to an end.
PHIO’s proprietary RNAi technology INTASYL™is designed to make immune cells more effective in killing tumor cells.
2024 could be a game-changing year for PHIO as it revolutionizes the way scientists think about precision medicine.
Learn More about Phio Pharmaceuticals by gaining access to the latest research report
Download ReportTHIS IS A PAID ADVERTISEMENT
NO INVESTMENT ADVICE
SCD Media LLC (d/b/a “Smallcaps Daily”), hereinafter referred to as “Smallcaps Daily,” and their affiliates and control persons (the “Publisher”) are in the business of publishing favorable information and/or advertisements (the “Information”) about the securities of publicly traded companies (each an “Issuer” or collectively the “Issuers”) in exchange for compensation (the “Campaigns”). Persons receiving the Information are referred to as the “Recipients.” The person or entity paying the Publisher for the Campaign is referred to herein as the “Paying Party”. The Paying Party may be an Issuer, an affiliated or non-affiliate shareholder of an Issuer, or another person hired by the Issuer or an affiliate or non-affiliate shareholder of the Issuer. The nature and amount of compensation paid to the Publisher for the Campaign and creating and/or publishing the Information about each Issuer is set forth below under the heading captioned, “Compensation”.
This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment.
Nothing on this website should be considered personalized financial advice. Any investments recommended herein should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.
Smallcaps Daily, its managers, its employees, affiliates, and assigns (collectively the "Publisher") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above.
Release of Liability: through use of this website, viewing or using you agree to hold Smallcaps Daily, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Smallcaps Daily encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the company profiled or is available from public sources and Smallcaps Daily makes no representations, warranties, or guarantees as to the accuracy or completeness of the disclosure by the profiled company. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Smallcaps Daily strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Smallcaps Daily’s full disclosure is to be read and fully understood before using Smallcaps Daily's website, or joining Smallcaps Daily's email or text list. From time to time, Smallcaps Daily will disseminate information about a company via website, email, sms, and other points of media. By viewing Smallcaps Daily's website and/or reading Smallcaps Daily's email or text newsletter you are agreeing to this ----> https://Smallcaps Daily.com/disclaimer/. All potential percentage gains discussed in any communications are based on calculations from the low to the high of the day. We are engaged in the business of marketing and advertising companies for monetary compensation.
If you have questions or concerns about a product you’ve seen in one of our emails, emails, text newsletters or SMS, we encourage you to reach out to that company directly.
Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by the owner of Smallcaps Daily. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to Smallcaps Daily. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here.
Smallcaps Daily is compliant with the CAN-SPAM Act of 2003. Smallcaps Daily does not offer investment advice or analysis, and Smallcaps Daily further urges you to consult your own independent tax, business, financial, and investment advisors. Investing in micro-cap, small-cap, and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. The private securities litigation reform act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events, or performance are not statements of historical fact but may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results in preparing this publication. Smallcaps Daily has relied upon information supplied by its clients, as well as its clients’ publicly available information and press releases which it believes to be reliable; however, such reliability can not be guaranteed. Investors should not rely on the information contained on this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, Smallcaps Daily and its owners, affiliates, subsidiaries, officers, directors, representatives, and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Smallcaps Daily is not responsible for any claims made by the companies advertised herein, nor is Smallcaps Daily responsible for any other promotional firm, its program, or its structure. Smallcaps Daily is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission, or FINRA.
Copyright © 2023 Smallcaps Daily. All rights reserved.